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Abstract
Background. Obesity is one of the main factors increasing mortality and the incidence of diseases of the cardiovas-
cular system. The base treatment is a non-pharmacological approach: diet and physical training. We see hypertension 
in obese people more often than in people of normal weight. The aim of this study was to answer the question of 
whether or not a 3-month comprehensive program of non-pharmacological treatment of obesity affects the circadian 
blood pressure profile.
Material and methods. The study was performed with 60 obese women aged 20–37 years who had an average body 
mass index (BMI) of 36 ± 4.9 kg/m2 and who declared their willingness to participate in the treatment of obesity. 
Qualified researchers proposed participation in the comprehensive, outpatient, non-pharmacological treatment pro-
gram for obesity. The program included activities with a dietician, physiotherapist and physician. Patients performed 
blood pressure measurements using 24-hour ambulatory monitoring (ABPM).
Results. After 3 months of treatment, the participants had a significant decrease in BMI and waist circumference. 
These changes were accompanied by a significant reduction in fasting insulin concentrations and a decrease in the 
insulin resistance index. Findings also showed a small but significant reduction in systolic blood pressure — circa-
dian, daytime and nighttime — and a reduction in the incidence characteristics of of ‘non-dipper’ pattern. In the 
study group significant positive correlations were found between the change in fasting insulin concentration and the 
change in circadian systolic blood pressure.
Conclusion. A non-pharmacological, comprehensive treatment program for obesity through weight reduction and 
a reduction of insulin resistance improves the profile of circadian systolic blood pressure and leads to the conversion 
of ‘non-dipper’ pattern to favourable ‘dipper’ pattern.
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Introduction
Obesity is one of the largest health problems in 
a consumer society as it leads to many complica-
tions, mainly involving the cardiovascular system, 
and is associated with increased mortality [1, 2]. In 
1998, the World Health Organization (WHO) iden-
tified obesity as a multifactorial chronic disease [3]. 
Increasing frequency of its occurrence is caused by 
the easy availability and excessive supply of food, 
a sedentary lifestyle and lack of exercise.
In the Pol-MONICA, area of Poland, we found 
obesity was prevalent in about 30% of women and 
20% of men [4, 5]. The goal of treatment of obesity 
is to reduce body weight by 5–10%, which is con-
sidered a sufficient weight loss to bring about health 
benefits. The time in which the target should be 
achieved is 3–6 months [6, 7].
It has been proven in a number of studies that 
weight loss of 5–30% can effectively reduce blood 
pressure, abnormal carbohydrate alignment and dys-
lipidaemia, and thus reduce the risk of complications 
of obesity and reduce mortality [8–10]. Hyperten-
sion is seen in obese people more often than in 
people of normal weight. It is believed that the pre-
disposition to hypertension does not correspond to 
obesity or metabolic disorders but it involves, above 
all, hyperinsulinaemia, insulin resistance and leptin 
resistance [11–15].
The organ complications and risk of cardiovascu-
lar events in the case of hypertension are determined 
not only by its absolute value but also its short- 
-term and circadian variability [16, 17]. Ambulatory 
blood pressure monitoring (ABPM) is used to assess 
the variability of blood pressure in clinical practice. 
Monitoring blood pressure over a 24-hour period 
has a better correlation with the incidence of organ 
complications of hypertension than blood pressure 
values obtained by office measurement. It also has 
an advantage in determining cardiovascular risk over 
traditional measurement [18, 19]. 
The aim of the current study was to answer the 
question of whether or not a 3-month comprehensive 
program involving the non-pharmacological treatment 
of obesity affects the circadian blood pressure profile.
Material and methods
The study was performed with 60 obese women, 
aged 20–37, who had an average body mass index 
(BMI) of 36 ± 4.9 kg/m2 and who declared their 
willingness to participate in the treatment of obesity. 
All women were informed about the purpose and 
design of the study and gave their written consent 
to participate.
The study protocol was approved by the Bioethical 
Commission of the Pomeranian Medical Universi-
ty at Szczecin. All patients who showed secondary 
forms of obesity by routine assay (e.g. thyroid corti-
sol test) were excluded. 
Women selected for the study agreed to partic-
ipate in a 3-month, comprehensive, outpatient, 
non-pharmacological treatment program for obesity. 
This program included activities with a dietician, 
physiotherapist and physician. The aim of the pro-
gram was to reduce body weight by 5–10% using 
non-pharmacological methods. 
Table I presents detailed clinical and biochemical 
characteristics of the study group.
Determinations of weight were made before treat-
ment (0) and at 3 months on the last day of con-
trolled, comprehensive treatment (3).
Patients reported, on an empty stomach, to 
an 8–9 am appointment at which anthropomet-
ric measurements were taken to assess weight and 
height and to calculate BMI and waist circumfe-
rence. In addition, blood samples were taken for 
biochemical and hormonal tests including total 
cholesterol, HDL, LDL and triglycerides, glucose, 
uric acid, and TSH and insulin levels. The bio-
chemical tests were determined by routine meth-
ods. Insulin resistance was calculated using the 
Table I. Baseline characteristics of patients in the studied group
Parameters Mean Range
Age (years) 33.5 20–37
Body mass index [kg/m2] 36 30–46
Waist circumference [cm] 104.0 88–126
Systolic blood pressure [mm Hg] 134.5 105–139
Diastolic blood pressure [mm Hg] 82.2 68–85
Total cholesterol [mg/dl] 192.5 119–267
LDL [mg/dl] 131.0 74–235
HDL [mg/dl] 50.0 27–89
Triglycerides [mg/dl] 132.3 33–285
Fasting glucose [mg/dl] 94.0 75–154
Uric acid [mg/dl] 5.6 2.8–11.5
eGFR [ml/min/1.73 m2] 72.4 60.2–90.5
Plasma cortisol [nmol/l] 309 86–486
Fasting insulin [uIU/ml] 13.9 5.2–40.8
IR 3.3 1.14–12.1
TSH [uIU/l] 1.57 0.48–3.88
LDL — low density lipoprotein, HDL — high density lipoprotein, eGFR — estimated glomerular filtra-
tion, IR — insulin resistance, TSH — thyroid stimulating hormone
arterial hypertension 2016, vol. 20, no. 2
70 www.ah.viamedica.pl
Table II. Comparison of mean (± SD) body mass index (BMI), waist circumference [WC], blood pressure (BP) values, its short-term variability (stan-
dard deviation), fasting insulin, and insulin resistance (IR) in the studied group at baseline (0) and after 3 months of active treatment (3)
Variable 0 3 D P-value
BMI [kg/m2]  36.0 ± 4.9  32.0 ± 4.9  –4.5 ± 3.3 p < 0.001
WC [cm]  104.0 ± 11.9  93.0 ± 13.7  10.8 ± 8.1 p < 0.001
24-hour systolic blood pressure [mm Hg]  117 ± 12  115 ± 11.6  –1.7 ± 8.9 p < 0.05
24-hour diastolic blood pressure [mm Hg]  72 ± 7.4  71 ± 7.6  0.65 ± 7.6 ns
Daytime systolic blood pressure [mm Hg]  120 ± 12.2  118 ± 11.4  –2.1 ± 8.4 p < 0.05
Daytime diastolic blood pressure [mm Hg]  76 ± 8.9  74 ± 7.4  –1.5 ± 6.1 ns
Nocturnal systolic blood pressure [mm Hg]  108 ± 12.0  105 ± 11.7  –2.6 ± 8.7 p < 0.05
Nocturnal diastolic blood pressure [mm Hg]  63 ± 7.9  60 ± 6.9  –1.5 ± 6.1 ns
Standard deviation [mm Hg]  11.6 ± 2.4  10.9 ± 1.9  –0.7 ± 2.5 ns
Fasting insulin  13.9 ± 7.9  9.8 ± 5.2  –4.1 ± 6.6 p < 0.02
IR  3.3 ± 2.3  2.3 ± 1.3  –1.1 ± 1.7 p < 0.001
D — change of parameters after active therapy
HOMA method [glucose concentration (mmol/L)] 
× fasting insulin (uU/mL/22.5).
The participants then started 24-hour Holter 
ambulatory pressure monitoring using an ABPM 
SpaceLabs 90207 measurement device. Blood pres-
sure monitoring was based on the oscillometric 
method. 24-hour registration of blood pressure mea-
surements started at 9 am and finished at the same 
time the next day. Measurements were made every 
20 minutes during the day (6 am–10 pm) and every 
30 minutes at night (10 pm–6 am), and then anal-
ysed by a computer program.
The study also evaluated the variability of the cir-
cadian average blood pressure, which was a measure 
of the standard deviation (SD) of all measurements 
during the day and night and average blood pressure 
drop daily (N/D). The study defined dipping pattern 
as a decrease in the average pressure at night of at 
least 10%, while non-dipping pattern was defined as 
an average pressure drop of less than 10% at night.
Statistical analysis was performed using the Statis-
tica software. The normality of the distribution was 
tested using the Shapiro-Wilk method. The charac-
teristics of independent variables with normal distri-
bution were examined using t-tests with an evaluation 
of homogeneity of variance. Features of the abnormal 
distribution were examined using nonparametric tests 
such as the Kolmogorov-Smirnov test. Dependent 
variables with normal distribution were tested using 
t-tests. Dependent variables with abnormal distribu-
tion were tested using the Wilcoxon test.
The analysis of measurable values’ mutual influ-
ence was performed using regression analysis for two 
trials. The analysis on immeasurable variables was 
carried out using Pearson’s chi-squared test and Fish-
er’s test for a small number of groups and the Mc-
Nemar test (nonparametric tests). All dependencies 
were considered statistically significant at p < 0.05.
Results
As shown in Table II, comprehensive, non-pharmaco-
logical treatment of obesity was very successful because 
after 3 months of treatment there was a significant 
reduction in participants’ BMI and waist circumfe -
rence. These changes were accompanied by a signif-
icant reduction in fasting insulin concentrations and 
a decrease in the insulin resistance index. There also 
were significant changes in systolic blood pressure. 
A small but significant reduction in circadian, day-
time and nighttime systolic blood pressure values was 
noted. The obesity treatment had no effect on diastolic 
blood pressure and short-term pressure variability.
Table III presents the distribution of dippers and 
non-dippers in the study population before treat-
ment and after 3 months of treatment. 
Non-pharmacological treatment of obesity af-
fected the blood pressure profile and significantly 
reduced (p < 0.005) the incidence of the disadvan-
tages of the absence of a reduction in blood pressure 
during the night. Baseline measurements showed 
Table III. Dippers versus non-dippers in the studied group at ba-
seline (0) and after 3 months of active treatment (3)
Studied group (n = 60)
Dippers Non-dippers
0 38 (63.3%) 22 (36.7%)
3 53 (88.7%) 7 (11.3%)
c2 statistic p < 0.005
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that 63.3% of participants (38 patients) were classi-
fied as dippers while 36.7% (22 patients) were clas-
sified as non-dippers. After 3 months of treatment, 
88.7% (53 patients) were classified as dippers and 
11.3% (7 patients) as non-dippers.
In the study group significant positive correlations 
were found between the change in fasting insulin con-
centration and the change in systolic blood pressure: 
circadian (r = 0.33, p < 0.02), daytime (r = 0.33, p < 
0.02) and nighttime (r = 0.38, p < 0.02) (Table Iv).
Discussion
In the present study, we used 24-hour automatic 
monitoring to evaluate the blood pressure and its 
changes under the influence of a weight-loss pro-
gram. For the entire study group, the mean circa-
dian, daytime and nighttime blood pressure values 
were correct. After 3 months of treatment, along 
with weight loss, there was a small decrease in cir-
cadian, daytime and nighttime blood pressure but 
only systolic pressure reached statistical significance. 
There was no marked reduction in blood pressure, 
despite a decrease in body weight and other para-
meters evaluated through anthropometric and hor-
mone tests.
In normotensive individuals, it is difficult to 
expect a reduction in blood pressure under the 
influence of weight loss, especially if these values 
are initially quite low. Probably, mechanisms are 
actuated to counteract such a reaction as proven by 
Itoh et al. [20].
Most studies have shown a link between a reduc-
tion in weight and reduction in blood pressure in 
patients with hypertension and developed complica-
tions of obesity [21, 22]. An interesting observation 
in our study has not been described in the literature. 
It appears that after 3 months of treatment, a signi-
ficant number of non-dippers developed a favourable 
dipping pattern. From the literature it is known 
that the overnight drop in blood pressure in healthy 
individuals is due to the dominance of the parasym-
pathetic system during sleep. In this aspect, it can 
be assumed that the dominance of the sympathetic 
nervous system at night leads to increased pressure 
and seizing of the circadian rhythm [23].
Generally, today no one denies that activities 
such as diet and exercise are effective methods for 
supporting the treatment of hypertension, and they 
sometimes are sufficient to eliminate the need for 
pharmacotherapy [24]. These are the recommenda-
tions of cardiological societies based on large, long-
-term, multi-centre studies such as the Framingham 
study [25, 26]. The ones who benefit, however, are 
sick people [27]. The more features of metabolic syn-
drome and cardiovascular complications, the greater 
the effect associated with reduction of body weight 
and correction of metabolic disorders.
As previously reported, levels of insulin can af-
fect blood pressure [12]. The present study found 
a positive correlation between insulin levels and 
mean systolic blood pressure circadian, daytime and 
nighttime. Insulin exerts a stimulatory effect on the 
sympathetic nervous system and an expressed impact 
on the systolic blood pressure values, which was con-
firmed by the correlation analysis.
For the obese population, the risk of cardiovas-
cular disease is most usefully measured by BMI and 
waist circumference. Waist circumference is the best 
predictor of developing metabolic syndrome due to 
the good reflectivity of visceral fat, regardless of gen-
der [28, 29]. Failing to take action to reduce weight 
leads to a higher degree of obesity and increasing 
metabolic disorders, predominantly insulin resis-
tance, which demonstrates that it is a chronic and 
progressive disease.
Conclusion
A non-pharmacological, comprehensive program to 
treat obesity through weight reduction and a re-
duction of insulin resistance improves the profile of 
circadian systolic blood pressure and leads to the 
conversion from non-dipper to a favourable dipper 
blood pressure profile.
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